Trial Profile
An Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Lumateperone (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- 10 May 2021 According to an Intra-Cellular Therapies media release, results from the study were presented at the American Psychiatric Association (APA) Annual Meeting 2021.
- 21 Jan 2021 According to an Intra-Cellular Therapies media release, results were recently published online in Schizophrenia Research.
- 21 Jan 2021 Results published in an Intra-Cellular Therapies media release.